ImmuCell Corporation Total Liabilities
ImmuCell Corporation total liabilities. Based on the latest financial reports, ImmuCell Corporation (ICCC) has total liabilities worth $15.26 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ImmuCell Corporation (ICCC) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ImmuCell Corporation (1989–2025)
Total liabilities of ImmuCell Corporation from 1989 to 2025. This chart illustrates how ImmuCell Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of ImmuCell Corporation to see how much of total assets are deployed in long-term investments.
ImmuCell Corporation Competitors by Total Liabilities
The table below lists competitors of ImmuCell Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RiTdisplay Corp
TW:8104
|
Taiwan | NT$5.27 Billion |
|
Intelligent Digital Integrated Security Co. Ltd
KQ:143160
|
Korea | ₩110.49 Billion |
|
GEA Grenobl. Elect.
PA:GEA
|
France | €16.51 Million |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
Indonesia | Rp8.56 Trillion |
|
Laramide Resources Ltd
AU:LAM
|
Australia | AU$5.95 Million |
|
Novem Group S.A.
XETRA:NVM
|
Germany | €447.70 Million |
|
Cellectis
PA:ALCLS
|
France | €226.30 Million |
|
Right Way Industrial Co Ltd
TW:1506
|
Taiwan | NT$426.92 Million |
Liability Composition Analysis (1989–2025)
This chart breaks down ImmuCell Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ImmuCell Corporation total assets.
Liquidity & Leverage Metrics
ImmuCell Corporation Total Liabilities Ratios Explained
ImmuCell Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImmuCell Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImmuCell Corporation (1989–2025)
The table below shows the annual total liabilities of ImmuCell Corporation from 1989 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.48 Million | -11.97% |
| 2024-12-31 | $17.58 Million | -6.55% |
| 2023-12-31 | $18.82 Million | +29.93% |
| 2022-12-31 | $14.48 Million | +21.80% |
| 2021-12-31 | $11.89 Million | -1.61% |
| 2020-12-31 | $12.08 Million | +24.57% |
| 2019-12-31 | $9.70 Million | -11.71% |
| 2018-12-31 | $10.99 Million | +2.64% |
| 2017-12-31 | $10.70 Million | +115.15% |
| 2016-12-31 | $4.98 Million | +24.79% |
| 2015-12-31 | $3.99 Million | +122.29% |
| 2014-12-31 | $1.79 Million | +14.61% |
| 2013-12-31 | $1.56 Million | -14.76% |
| 2012-12-31 | $1.84 Million | -6.86% |
| 2011-12-31 | $1.97 Million | +34.18% |
| 2010-12-31 | $1.47 Million | +304.88% |
| 2009-12-31 | $362.77K | -25.12% |
| 2008-12-31 | $484.49K | +36.28% |
| 2007-12-31 | $355.52K | -82.50% |
| 2006-12-31 | $2.03 Million | +45.36% |
| 2005-12-31 | $1.40 Million | -22.38% |
| 2004-12-31 | $1.80 Million | +120.64% |
| 2003-12-31 | $816.18K | +46.06% |
| 2002-12-31 | $558.78K | -47.83% |
| 2001-12-31 | $1.07 Million | +18.35% |
| 2000-12-31 | $904.92K | -13.04% |
| 1999-12-31 | $1.04 Million | +15.62% |
| 1998-12-31 | $900.00K | 0.00% |
| 1997-12-31 | $900.00K | -25.00% |
| 1996-12-31 | $1.20 Million | -7.69% |
| 1995-12-31 | $1.30 Million | +8.33% |
| 1994-12-31 | $1.20 Million | +50.00% |
| 1993-12-31 | $800.00K | +60.00% |
| 1992-12-31 | $500.00K | -28.57% |
| 1991-12-31 | $700.00K | +16.67% |
| 1990-12-31 | $600.00K | 0.00% |
| 1989-12-31 | $600.00K | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more